IP Library › Granted Patent US 12,281,309
Granted Patent B1
US 12,281,309 · App. 18/889,137 · Granted Apr 22, 2025

Composition for regulating production of interfering ribonucleic acid

Inventor: Bradley G. Thompson (Calgary, CA)
Assignee: Wyvern Pharmaceuticals Inc.
C12N15/1137C12N15/86C12N2310/141C12N2750/14143
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,281,309
App. No.
18/889,137
Granted
Apr 22, 2025
Kind
B1
Abstract

The embodiments of the present disclosure relate to one or more compositions or methods that upregulate the production of one or more sequences of micro-interfering ribonucleic acid (miRNA). The sequences of miRNA may be complimentary to a sequence of target messenger RNA (mRNA) that encodes for translation of a target biomolecule, such as JAK. The miRNA can cause the target mRNA to be degraded or inactivated, thereby causing a decrease in bioavailability of the target biomolecule because it is degraded or inactivated by the miRNA. Decreasing the bioavailability of the target biomolecule within a subject that is administered the one or more compositions may address the afflictions experienced by the subject due to expression of the target biomolecule.

Claims (6)

1. A composition that comprises a recombinant plasmid (RP) with an insert sequence of nucleotides that comprises 95-100% identity to the full length of SEQ ID NO: 2.

2. The composition of claim 1 , wherein the insert sequence of nucleotides is encased in a protein coat, a lipid vesicle, or any combination thereof.

3. The composition of claim 1 , wherein the insert sequence of nucleotides is encased in a viral vector.

4. The composition of claim 3 , wherein the viral vector is one of a double stranded DNA virus, a single stranded DNA virus, a single stranded RNA virus, or a double stranded RNA virus.

5. The composition of claim 3 , wherein the viral vector is an adeno-associated virus.

6. A composition that comprises a recombinant plasmid (RP) with a sequence of nucleotides that encodes for a kinase molecule, wherein the sequence comprises 95-100% identity to the full length of SEQ ID NO. 3.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 29, 2025
From: THOMPSON, BRADLEY G.
To: WYVERN PHARMACEUTICALS INC.
Reel/Frame 072412/0362 →
References Cited (6)
O'Brien et al. “Overview of MicroRNA Biogenesis, Mechanisms of Actions, and Circulation,” Frontiers in Endocrinology, vol. 9, Article 402: 1-12 (2018). (Year: 2018). [cited by examiner]
Zhang et al. “The Risks of miRNA Therapeutics: In a Drug Target Perspective,” Drug Design, Development and Therapy 15: 721-733 (2021). (Year: 2021). [cited by examiner]
Ha et al. “Interspecies Regulation of MicroRNAs and Their Targets,” Biochim Biophys Acta. 1779(11): 735-742 (2008). (Year: 2008). [cited by examiner]
Taylor & Kornev “Protein kinases: evolution of dynamic regulatory proteins,” Trends in Biochemical Sciences, vol. 36, Issue 2, 65-77 (2011). (Year: 2011). [cited by examiner]
Scheef & Bourne. “Structural evolution of the protein kinase-like superfamily,” PLoS Comput Biol. Oct. 2005;1(5):e49. (Year: 2005). [cited by examiner]
Ramaiah et al. “miR-15/16 complex targets p70S6 kinase1 and controls cell proliferation in MDA-MB-231 breast cancer cells,” Gene , vol. 552, Issue 2, Dec. 1, 2014, pp. 255-264. (Year: 2014). [cited by examiner]
Cited By (18)
US 12,509,692 US 12,509,693 US 12,516,327 US 12,516,328 US 12,522,831 US 12,522,832 US 12,522,833 US 12,534,733 US 12,540,328 US 12,540,329 US 12,553,051 US 12,553,052 US 12,559,756 US 12,565,652 US 12,565,655 US 12,565,657 US 12,644,124 US 12,680,103